The table below shows Aligos Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$23.13M
-$20.91M
-$22.75M
-$22.39M
-$20.43M
-$29.80M
Capital expenditure
-
-
-
$7.00K
$515.00K
$307.00K
Investing cash flow
$34.93M
-$44.07M
-$88.64M
$19.99M
-$60.40M
$9.69M
Dividends paid
-
-
-
-
ALGS operating cash flow (10-K history)
Aligos Therapeutics, Inc. reported operating cash flow of -$82.50M for fiscal year 2025. That is down 2.2% from -$80.74M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$46.77M (FY 2019) to -$82.50M. Figures come from the company's audited annual reports as filed with the SEC.